Safety and Efficacy of Finerenone in Diabetic Kidney Disease: A Single-Center Retrospective Real-World Comparative Study of Dosing and Clinical Decision-Making in Taiwan [PDF]
PharmaceuticalsBackground: Finerenone improves cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes, but its early real-world effect on albuminuria, the relative safety and effectiveness of standard versus reduced-dose regimens, and the ...
Jui-Ting Hsu +13 more
doaj +2 more sources
A comparative real-world analysis of finerenone and steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease [PDF]
Frontiers in PharmacologyBackgroundFinerenone and steroidal mineralocorticoid receptor antagonists (sMRAs) reduce proteinuria in chronic kidney disease (CKD), but direct comparative data from routine clinical practice remain limited.
Daniele Vetrano +17 more
doaj +2 more sources
Association of finerenone with graded proteinuria improvement in type 2 diabetes with chronic kidney disease and proteinuria >1 g/d: a retrospective cohort study [PDF]
Frontiers in EndocrinologyBackgroundCurrent evidence for finerenone in T2DM with CKD is derived primarily from patients with microalbuminuria to macroalbuminuria, and data in those with moderate-to-heavy proteinuria remain limited.
Na Sun +5 more
doaj +2 more sources
SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis [PDF]
Frontiers in PharmacologyBackgroundDespite optimal renin-angiotensin system (RAS) blockade, patients with diabetic kidney disease (DKD) face substantial residual cardiorenal risk.
Zongze He +3 more
doaj +2 more sources
Metabolism Open, 2023 Background: In the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial, finerenone reduced the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes, while in the ...
Akira Mima +8 more
doaj +1 more source
Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease
Kidney & Blood Pressure Research, 2022 Background: The phase III clinical trial of the nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) has been completed, aiming to investigate renal and cardiovascular outcomes in type 2 diabetes (T2D) with chronic kidney disease ...
Yaning Zheng +6 more
doaj +1 more source
Cardiovascular Diabetology, 2023 Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with high binding affinity, high MR selectivity and a short plasma half-life.
Ulrich Kintscher, Frank Edelmann
doaj +1 more source
Kidney Diseases, 2023 Background: This prespecified subgroup analysis of the FIDELIO-DKD trial aimed to evaluate the efficacy and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) in China.
Haitao Zhang +13 more
doaj +1 more source
Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus [PDF]
Endocrinology and Metabolism, 2022 Type 2 diabetes mellitus (T2DM) and cardiovascular disease are closely interconnected. We sought to determine the cardioprotective action of finerenone according to prior treatment with newer antidiabetics and glycemic status.
Dimitrios Patoulias +4 more
doaj +1 more source
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. [PDF]
PLoS ONE, 2017 The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidney disease.
Jochen Dutzmann +8 more
doaj +1 more source